依立雄胺对雄激素非依赖前列腺癌细胞DU-145的作用

外科研究与新技术 ›› 2012, Vol. 1 ›› Issue (2): 135-138.

依立雄胺对雄激素非依赖前列腺癌细胞DU-145的作用

李涛¹, 李玉华², 李润生², 桂亚平¹, 卞崔冬¹, 黄盛松¹, 吴登龙¹

¹ 上海市同济医院泌尿外科 200065; ²上海市计划生育科学研究所

出版日期:2012-12-28 发布日期:2012-02-25
通讯作者: 吴登龙.E-mail:wudenglong@163.com
作者简介:李涛(1968-), 男, 医学博士, 主要从事前列腺癌的临床基础研究

Effects of epristeride on human prostate carcinoma cell Line DU-145

Li Tao¹, Li Yu-Hua², Li Run-Sheng², Gui Ya-Ping¹, Bian Cui-Dong¹, Huang Shen-Song¹, Wu Deng-Long¹

¹Department of Urology ,Shanghai Tongji Hospital,Shanghai 200065; ²Shanghai Institute of Planned Parenthood Research

Online:2012-12-28 Published:2012-02-25

摘要/Abstract

摘要： 目的为研究依立雄胺治疗前列腺癌的可能性及可能机制, 探讨依立雄胺体外对人激素非依赖型前列腺癌细胞( DU-145) 生长的作用。方法用2.5, 5, 10, 20和40 μM的依立雄胺作用DU-145细胞3天后, 用普通倒置显微镜进行细胞形态学观察; 用黄酰罗丹明B法(SRB法)评价依立雄胺对前列腺癌细胞株DU-145的体外增殖抑制作用绘制的生长曲线; 应用流式细胞仪评价依立雄胺对对前列腺癌细胞株DU-145的周期阻滞作用。结果 40 μM和20 μM的依立雄胺作用DU-145细胞3 d 后, 可使其明显的皱缩凋亡;依立雄胺对DU-145呈现明显的浓度依赖的体外增殖抑制作用;通过流式细胞仪分析发现, 依立雄胺对DU-145呈现明显的浓度依赖的周期阻滞作用。

关键词: 依立雄胺, 凋亡, 增殖, 黄酰罗丹明B法(SRB法), 细胞株, DU-145, 前列腺癌

Abstract: Objective To study the possibility and potential mechanisms of epristeride treatment of prostate cancer,and to investigate the effect of epristeride on the growth of DU-145 cells in vitro.Method We used different concentration of epristeride (2.5,5,10,20,40mM) to interfere DU145 cells and used an inverted microscope to observe the cell morphology.We used Sulforhodamine B(SRB) to evaluate the growth curve characterized by the inhibition of in vitro proliferation of DU145 cells caused by epristeride.We applied flow cytometry to evaluate cell cycle arrest of DU145 induced by epristeride.Results An obvious cell shrinkage and apoptosis was observed three days after the interference of epristeride with the concentration of 40mM and 20mM.Epristeride shows a conspicuously concentration-dependent inhibition of in vitro proliferation of DU145 cells.Through flow cytometry,we found that epristeride demonstrated a highly Concentration dependent effect of causing cell cycle arrest in DU145 cell line.

Key words: Epristeride, Apoptosis, Cell proliferation, Sulforhodamine B, Cell line, DU145, Prostate cancer

中图分类号:

R 737.25

李涛, 李玉华, 李润生, 桂亚平, 卞崔冬, 黄盛松, 吴登龙. 依立雄胺对雄激素非依赖前列腺癌细胞DU-145的作用[J]. 外科研究与新技术, 2012, 1(2): 135-138.

Li Tao, Li Yu-Hua, Li Run-Sheng, Gui Ya-Ping, Bian Cui-Dong, Huang Shen-Song, Wu Deng-Long. Effects of epristeride on human prostate carcinoma cell Line DU-145[J]. 外科研究与新技术, 2012, 1(2): 135-138.

参考文献

[1] Jemal AS,Rebecca Xu JW,Elizabeth.Cancer Statistics[J].CA CANCER J CLIN,2010,60(5):23.
[2] 刘振伟,项永兵,张薇,等.上海市区1973～1999年前列腺癌发病趋势分析[J].中国卫生统计,2003,20(6):335-337.
[3] 吴海涵,翁志梁,李湘斌,等.5α-还原酶抑制剂治疗对前列腺增生患者血清性激素水平的影响[J].中国男科学杂志,2007,21(3):44-46.
[4] Russell DW,Wilson JD.Steroid 5 alpha-reductase: two genes/two enzymes[J].Annu Rev Biochem,1994,63(1):25-61.
[5] 刘本,常忆凌,陈科力.5α还原酶作为天然药物筛选靶的研究进展[J].药物生物技术,2006,13(6):468-470.
[6] 王梦芝.良性前列腺增生症的药物治疗进展[J].当代医学,2010,16(14):24-26.
[7] 孙华君,刘少明.5α还原酶抑制剂临床研究进展[J].世界临床药物,2006,27(2):95-101.
[8] Zu-Yue Sun WZ,Jie Feng ZT.A convenient and rapid method to study enzymatic kinetics of steroid 5a-reductase inhibitors[J].Indian Journal of Pharmacology,1998,30(4):257-262.
[9] Schafhauser W EA,Kiihn R KH,Culig Z.Effect of epristeride and bicalutamide on human prostate cancer PCEW on the nude mouse mode[J].J Eur Urol,1998,34(3):252-253.
[10] Sun ZY,Feng J,Qi XD,et al.Reversible long-term toxicity of epristeride in beagle dogs[J].Toxicol Appl Pharmacol,1999,154(2):145-52.
[11] Wu SF,Sun HZ,Qi XD,et al.Effect of epristeride on the expression of IGF-1 and TGF-beta receptors in androgen-induced castrated rat prostate[J].Exp Biol Med (Maywood),2001,226(10):954-60.
[12] Wu SF,Sun HZ,Tu ZH,et al.Inhibition of cultured rat prostatic epithelial cell growth by epristeride in vitro[J].Acta Pharmacol Sin,2001,22(3):257-63.
[13] John C.Lamb JTI,Mark A.Levy RKJ.Response of rat and human prostatic cancers to the novel 5-reductase inhibitor[J].SK&F 105657.Prostate,1992,21(1):15-34.